PhD, Associate Professor at the Cardiology Department,
1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412
PhD, Associate Professor at the Cardiology Department,
1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412
MD, Ph.D., Associate Professor, and Head of the Department of Clinical Cardiology,
6, Sosnoviy Blvd., Kemerovo,650002
MD, Ph.D., Associate Professor, and Head of the Department of Clinical Cardiology,
6, Sosnoviy Blvd., Kemerovo,650002
PhD, Associate Professor, 1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412;
Medical Director, 69/1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628400
PhD, Associate Professor, 1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412;
Medical Director, 69/1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628400
PhD, Professor, Head of the Laboratory of Urgent therapy,
175/1, B. Bogatkova St., Novosibirsk, 630089
PhD, Professor, Head of the Laboratory of Urgent therapy,
175/1, B. Bogatkova St., Novosibirsk, 630089
PhD, Professor, Director of the Medical Institution, Chairperson of the Department of Pathophysiologyand General Pathology,
1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412
PhD, Professor, Director of the Medical Institution, Chairperson of the Department of Pathophysiologyand General Pathology,
1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628412
cardiologist, Head of the Department of Department of hospitalization with a telemedicine center,
69/1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628400
cardiologist, Head of the Department of Department of hospitalization with a telemedicine center,
69/1, Lenin Ave., Surgut, Khanty-Mansiysk Autonomous Okrug − Yugra, 628400
Aim. To assess the dynamic changes and clinical significance of biomarkers of inflammatory processes in patients with acute myocardial infarction (MI) with/ or without type 2 diabetes mellitus (T2DM) and primary percutaneous coronary intervention (pPCI) at various stages of treatment.
Methods. 96 patients with acute MI after pPCI were examined. The level of inflammation markers was measured 4 times: before pPCI (first day from admission to the hospital), on the third day, 7–10 days (before discharge from the hospital) and 40–45 days after pPCI.
Results. All groups of patients with MI showed an increase in the plasma activity of biomarkers of inflammatory processes. After pPCI for 40–45 days, there is a significant difference in the concentration of biomarkers, depending on the comorbid T2DM presence. Strong associations were found between cardiovascular biomarkers and post-MI cardiac remodeling and coronary atherosclerosis progression.
Conclusion. The assessment of the levels of biomarkers of inflammatory processes may have additional clinical value in estimating the course of MI, including patients with T2DM at the postinfarction stages.
Aim. To assess the dynamic changes and clinical significance of biomarkers of inflammatory processes in patients with acute myocardial infarction (MI) with/ or without type 2 diabetes mellitus (T2DM) and primary percutaneous coronary intervention (pPCI) at various stages of treatment.
Methods. 96 patients with acute MI after pPCI were examined. The level of inflammation markers was measured 4 times: before pPCI (first day from admission to the hospital), on the third day, 7–10 days (before discharge from the hospital) and 40–45 days after pPCI.
Results. All groups of patients with MI showed an increase in the plasma activity of biomarkers of inflammatory processes. After pPCI for 40–45 days, there is a significant difference in the concentration of biomarkers, depending on the comorbid T2DM presence. Strong associations were found between cardiovascular biomarkers and post-MI cardiac remodeling and coronary atherosclerosis progression.
Conclusion. The assessment of the levels of biomarkers of inflammatory processes may have additional clinical value in estimating the course of MI, including patients with T2DM at the postinfarction stages.
The authors declare that there are no conflicts of interest present.